Hypercoagulability, D-dimer and atrial fibrillation: An overview of biological and clinical evidence

Annals of Medicine

Volumn 46, Issue 6, 2014, Pages 364-371

  Danese, Elisa ^a   Montagnana, Martina ^a   Cervellin, Gianfranco ^b   Lippi, Giuseppe ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b ACADEMIC HOSPITAL OF PARMA   (Italy)

Author keywords

Atrial fibrillation; D dimer; Hypercoagulability; Stroke; Thrombosis

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; D DIMER; DABIGATRAN; WARFARIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTIFICIAL EMBOLISM; BLOOD CLOTTING; BRAIN EMBOLISM; BRAIN INFARCTION SIZE; CARDIOVERSION; CLINICAL DECISION MAKING; DEATH; DISEASE ASSOCIATION; DYSKINESIA; FIBRINOLYSIS; GOLD STANDARD; HEART ATRIUM CONTRACTION; HEART ATRIUM FIBRILLATION; HEART ATRIUM THROMBOSIS; HUMAN; HYPERCOAGULABILITY; PATHOPHYSIOLOGY; PATIENT CARE; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; REVIEW; RISK ASSESSMENT; RISK FACTOR; SINUS RHYTHM; THROMBOEMBOLISM; ATRIAL FIBRILLATION; BLOOD; COMPLICATION; THROMBOPHILIA; THROMBOSIS;

ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; THROMBOPHILIA; THROMBOSIS;

EID: 84907056935     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.912835     Document Type: Review

References (76)

1. Go AS, Mozaff arian D , R oger V L, B enjamin E J, B erry J D, B orden W B, et al. ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013 ; 127 : e6-245
2. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener HC, et al. Outcome parameters for trials in atrial fi brillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). Eur Heart J. 2007; 28: 2803-17
3. Franco D, Chinchilla A, Ar ánega AE. Transgenic insights linking pitx2 and atrial arrhythmias. Front Physiol. 2012; 3: 206
4. Benjamin EJ, Rice KM, Arking DE, Pfeufer A, van Noord C, Smith AV, et al. Variants in ZFHX3 are associated with atrial fi brillation in individuals of European ancestry. Nat Genet. 2009 ; 41 : 879-81
5. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, et al. Common variants in KCNN3 are associated with lone atrial fi brillation . Nat Genet. 2010 ; 42 : 240-4
6. Ellinor PT, Lunetta KL, Albert CM, Glazer NL, Ritchie MD, Smith AV, et al. Meta-Analysis identifi es six new susceptibility loci for atrial fi brillation . Nat Genet. 2012 ; 44 : 670-5
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. ; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fi brillation: an update of the 2010 ESC Guidelines for the management of atrial fi brillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 ; 33 : 2719-47
8. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci A, et al. ; ASSERT Investigators. Subclinical atrial fi brillation and the risk of stroke. N Engl J Med. 2012; 366: 120-9
9. Verma A, Champagne J, Sapp J, Essebag V, Novak P, Skanes A, et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fi brillation before and aft er catheter ablation (DISCERN AF): a prospective, multicenter study. JAMA Intern Med. 2013; 173: 149-56
10. Jahangir A, Lee V, Friedman PA, Trusty JM, Hodge DO, Kopecky SL, et al. Long-Term progression and outcomes with aging in patients with lone atrial fi brillation: a 30-year follow-up study. Circulation. 2007 ; 115 : 3050-6
11. Soliman EZ, Saff ord MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA , et al. Atrial fi brillation and the risk of myocardial infarction. JAMA Intern Med. 2014; 174: 107-14
12. Dukes JW, Marcus GM. Atrial fi brillation begets myocardial infarction. JAMA Intern Med. 2014; 174: 5-7
13. Maisel WH, Stevenson LW. Atrial fi brillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol. 2003 ; 91 : 2D-8D.
14. Wang TJ, Larson MG, Levy D, Vasan RS, Leip EP, Wolf PA, et al. Temporal relations of atrial fi brillation and congestive heart failure and their joint infl uence on mortality: the Framingham Heart Study. Circulation. 2003 ; 107 : 2920-5
15. Lip GY. Does atrial fi brillation confer a hypercoagulable state? Lancet. 1995 ; 346 : 1313-14
16. Takahashi Y, Takahashi A, Kuwahara T, Okubo K, Fujino T, Takagi K , et al. Renal function aft er catheter ablation of atrial fi brillation. Circulation. 2011 ; 124 : 2380-7
17. Bansal N, Fan D, Hsu CY, Ordonez JD, Marcus GM, Go AS. Incident atrial fi brillation and risk of end-stage renal disease in adults with chronic kidney disease. Circulation. 2013; 127: 569-74
18. Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fi brillation: a clinical review. Eur Heart J. 2013 ; 34 : 1475-80
19. Choudhury A, Lip GY. Atrial fi brillation and the hypercoagulable state: from basic science to clinical practice. Pathophysiol Haemost Th romb. 2003-2004 ; 33 : 282-9
20. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Th romb Hemost. 2008; 34: 747-61
21. Miyazaki S, Ito T, Suwa M, Nakamura T, Kobashi A, Kitaura Y. Role of transesophageal echocardiography in the prediction of thromboembolism in patients with chronic nonvalvular atrial fi brillation. Jpn Circ J. 2001 ; 65 : 874-8
22. Kamp O, Verhorst PM, Welling RC, Visser CA. Importance of left atrial appendage fl ow as a predictor of thromboembolic events in patients with atrial fi brillation. Eur Heart J. 1999 ; 20 : 979-85
23. Sanfi lippo AJ, Abascal VM, Sheehan M, Oertel LB, Harrigan P, Hughes RA, et al. Atrial enlargement as a consequence of atrial fi brillation. A prospective echocardiographic study. Circulation. 1990 ; 82 : 792-7
24. Keren G, Etzion T, Sherez J, Zelcer AA, Megidish R, Miller HI, et al. Atrial fi brillation and atrial enlargement in patients with mitral stenosis. Am Heart J. 1987; 114: 1146-55
25. P redictors of thromboembolism in atrial fi brillation: II. E chocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992; 116: 6-12
26. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fi brillation: Virchow' s triad revisited. Lancet. 2009; 373: 155-66
27. Goldsmith IR, Blann AD, Patel RL, Lip GY. Von Willebrand factor, fi brinogen, and soluble P-selectin levels aft er mitral valve replacement versus mitral valve repair. Am J Cardiol. 2000; 85: 1218-22
28. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW , et al. ; for the Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Aortic plaque in atrial fi brillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999 ; 30 : 834-40
29. T ransesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fi brillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography . Ann Intern Med. 1998; 128: 639-47
30. Kaski JC, Arrebola-Moreno AL. Infl ammation and thrombosis in atrial fi brillation. Rev Esp Cardiol. 2011; 64: 551-3
31. Boos CJ, Anderson RA, Lip GY. Is atrial fi brillation an infl ammatory disorder? Eur Heart J. 2006; 27: 136-49
32. Chung NA, Belgore F, Li-Saw-Hee FL, Conway DS, Blann AD, Lip GY. Is the hypercoagulable state in atrial fi brillation mediated by vascular endothelial growth factor? Stroke. 2002 ; 33 : 2187-91
33. Marin F, Roldan V, Climent V, Garcia A, Marco P, Lip GY. Is thrombogenesis in atrial fi brillation related to matrix metalloproteinase-1 and its inhibitor TIMP-1? Stroke. 2003; 34: 1181-6
34. Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fi brillation . Circulation. 2002 ; 106 : 1962-7
35. Kamath S, Blann AD, Lip GY. Platelets and atrial fi brillation. E ur Heart J. 2001 ; 22 : 2233-42
36. Ló pez-Cuenca A, Mar ín F, Rold án V, Gonz ález-Conejero R, Hern ández-Romero D , Valdés M, et al. Genetic polymorphisms and atrial fi brillation: insights into the prothrombotic state and thromboembolic risk. Ann Med. 2010; 42: 562-75
37. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fi brillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010; 31: 2369-429
38. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refi ning clinical risk stratifi cation for predicting stroke and thromboembolism in atrial fi brillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010 ; 137 : 263-72
39. Lippi G, Cervellin G, Franchini M, Favaloro EJ. Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future. J Th romb Th rombolysis. 2010; 30: 459-71
40. Lippi G, Franchini M, Targher G, Favaloro EJ. Help me, Doctor! My D-dimer is raised. Ann Med. 2008; 40: 594-605
41. Lip GY, Lowe GD, Rumley A, Dunn FG. Fibrinogen and fi brin D-dimer levels in paroxysmal atrial fi brillation: evidence for intermediate elevated levels of intravascular thrombogenesis. Am Heart J. 1996 ; 131 : 724-30
42. Marin F, Roldan V, Climent VE, Ibanez A, Garcia A, Marco P, et al. Plasma von Willebrand factor, soluble thrombomodulin, and fi brin D-dimer concentrations in acute onset non-rheumatic atrial fi brillation. Heart. 2004 ; 90 : 1162-6
43. Inoue H, Nozawa T, Okumura K, Lee JD, Shimizu A, Yano K. Prothrombotic activity is increased in patients with nonvalvular atrial fi brillation and risk factors for embolism. Chest. 2004; 126: 687-92
44. Lip GY, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fi brillation: eff ects of warfarin therapy. Br Heart J. 1995 ; 73 : 527-33
45. Sadanaga T, Mitamura H, Fukuda K, Ogawa S. D-dimer levels positively correlate with B-Type natriuretic peptide levels in patients with atrial fi brillation. Int J Cardiol. 2012; 158: 110-11
46. Lippi G, Cervellin G, Casagranda I, Morelli B, Testa S, Tripodi A. D-dimer testing for suspected venous thromboembolism in the emergency department. Consensus document of AcEMC, CISMEL, SIBioC, and SIMeL. Clin Chem Lab Med. 2014; 52: 621-8
47. Verma N, Willeke P, Bics án P, Lebiedz P, Pavenstädt H, Kümpers P. Age-Adjusted D-dimer cut-off s to diagnose thromboembolic events. Validation in an emergency department. Med Klin Intensivmed Notfmed. 2014; 109: 121-8. [German]
48. L ippi G , B onfanti L , S accenti C , C ervellin G. C auses of elevated D-dimer in patients admitted to a large urban emergency department. Eur J Intern Med. 2014; 25: 45-8
49. Douma RA, Tan M, Schutgens RE, Bates SM, Perrier A, Legnani C, et al. Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded. Haematologica. 2012; 97: 1507-13
50. Penaloza A, Roy P-M, Kline J, Verschuren F, Le Gal G, Quentin-Georget S, et al. Performance of age-Adjusted D-dimer cut-off to rule out pulmonary embolism. J Th romb Haemost. 2012; 10: 1291-6
51. Schouten HJ, Geersing GJ, Koek HL, Zuithoff NPA, Janssen KJM, Douma RA, et al. Diagnostic accuracy of conventional or age adjusted D-dimer cut-off values in older patients with suspected venous thromboembolism: systematic review and meta-Analysis. BMJ. 2013 ; 346 : f2492
52. Legnani C, Cini M, Cosmi B, Carraro P, Tripodi A, Erba N, et al. Age and gender specifi c cut-off values to improve the performance of D-dimer assays to predict the risk of venous thromboembolism recurrence. Intern Emerg Med. 2013; 8: 229-36
53. Gallagher MM, Hennessy BJ, Edvardsson N, Hart CM, Shannon MS, Obel OA , et al. Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol. 2002; 40: 926-33
54. Yasaka M, Miyatake K, Mitani M, Beppu S, Nagata S, Yamaguchi T, et al. Intracardiac mobile thrombus and D-dimer fragment of fi brin in patients with mitral stenosis. Br Heart J. 1991; 66: 22-5
55. Heppell RM, Berkin KE, McLenachan JM, Davies JA. Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fi brillation. Heart. 1997 ; 77 : 407-11
56. S omloi M , T omcsanyi J , N agy E , B odó I , B ezzegh A. D -dimer determination as a screening tool to exclude atrial thrombi in atrial fi brillation. Am J Cardiol. 2003; 92: 85-7
57. Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, et al. Prediction of left atrial appendage thrombi in non-valvular atrial fi brillation. Eur Heart J. 2007 ; 28 : 2217-22
58. Body R, Allie B. Towards evidence based emergency medicine: best BETs from the Manchester Royal Infi rmary. Negative D-dimer may allow safe early cardioversion of atrial fi brillation. Emerg Med J. 2007 ; 24 : 432-5
59. Mahé I, Bergmann JF , Chassany O, dit-Sollier CB, Simoneau G, Drouet L ; COAGFA Group. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fi brillation . Th romb Res. 2012; 129: 693-9
60. Mah é I, Drouet L, Simoneau G, Minh-Muzeaux S, Caulin C, Bergmann JF. D-dimer can predict survival in patients with chronic atrial fi brillation. Blood Coagul Fibrinolysis. 2004; 15: 413-17
61. Krarup LH, Sandset EC, Sandset PM, Berge E. D-dimer levels and stroke progression in patients with acute ischemic stroke and atrial fi brillation. Acta Neurol Scand. 2011; 124: 40-4
62. Rold án V, Mar ín F, Mui ña B, Torregrosa JM, Hern ández-Romero D, Valdés M, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fi brillation patients. J Am Coll Cardiol. 2011 ; 57 : 2496-504
63. Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fi brillation During oral anticoagulant therapy. J Am Coll Cardiol. 2010 ; 55 : 2225-31
64. S adanaga T , K ohsaka S , O gawa S. D -dimer levels in combination with clinical risk factors can eff ectively predict subsequent thromboembolic events in patients with atrial fi brillation During oral anticoagulant therapy . Cardiology. 2010; 117: 31-6
65. Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD, et al. D-dimer level infl uences thromboembolic events in patients with atrial fi brillation. Int J Cardiol. 2006; 109: 59-65
66. Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fi brillation During oral anticoagulant therapy. Th romb Haemost. 2003; 90: 1163-72
67. Matsumoto M, Sakaguchi M, Okazaki S, Furukado S, Tagaya M, Etani H, et al. Relationship between plasma (D)-dimer level and cerebral infarction volume in patients with nonvalvular atrial fi brillation. Cerebrovasc Dis. 2013; 35: 64-72
68. Lip GY, Rumley A, Dunn F, Lowe G. Plasma fi brinogen and fi brin D-dimer levels in paroxysmal atrial fi brillation: eff ects of cardioversion to sinus rhythm. Int J Cardiol. 1995; 51: 245-51
69. Hatzinikolaou-Kotsakou E, Hatseras DI. The potential of D-dimer levels as a useful clinical marker of clotting state aft er the return of sinus rhythm. Future Cardiol. 2006; 2: 55-61
70. Hatzinikolaou-Kotsakou E, Kartasis Z, Tziakas D, Stakos D, Hotidis A, Chalikias G , et al. Clotting state aft er cardioversion of atrial fi brillation: a haemostasis index could detect the relationship with the arrhythmia duration. Th romb J. 2005 ; 3 : 2
71. Lip GY, Lip P, Zarifi s J, Watson RD, Bareford D, Lowe GD, et al. Fibrin D-dimer and thrombomodulin as markers of thrombogenesis and platelet activation in atrial fi brillation. Eff ects of introducing ultralow-dose warfarin and aspirin. Circulation. 1996; 94: 425-31
72. Nakatani Y, Mizumaki K, Nishida K, Hirai T, Sakabe M, Oda Y, et al. Anticoagulation control quality aff ects the D-dimer levels of atrial fi brillation patients. Circ J. 2012 ; 76 : 317-21
73. Fuster V, Ryd é n LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC Guidelines for the management of patients with atrial fi brillation: executive summary. Circulation. 2001; 104: 2118-50
74. Sairaku A, Yoshida Y, Hirayama H, Nakano Y, Kihara Y. Periprocedural coagulability in patients undergoing ablation of atrial fi brillation: lessons from a periablation anticoagulation strategy of a brief withdrawal of warfarin without heparin bridging. J Th romb Th rombolysis. 2014 ; 37 : 393-9
75. Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, et al. A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fi brillation . Pacing Clin Electrophysiol. 2013; 36: 172-9
76. Tayebjee MH, Lip GY. Fibrin D-dimer levels in atrial fi brillation as an index of thrombogenesis: a possible test to exclude left atrial thrombus? Am J Cardiol. 2003; 92: 47-9